Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population.
- Status
- recruiting
- Phase
- Early Phase 1
- Institution
- Johns Hopkins University
- Principal investigator
- Ambereen K Mehta, MD, MPH, FAAHPM
- Start date
- 2025-04-09
- End date
- 2027-07-01
- Registry ID
- NCT06656702
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.